NeoGenomics Stock Plunges After Patent Infringement Ruling In Favor Of Natera
(RTTNews) - Shares of oncology testing services company, NeoGenomics, Inc. (NEO) stock tumbled 16.49% after Natera won preliminary Injunction in patent infringement suit against NeoGenomics' RaDaR Test.
A district judge has barred NeoGenomics from making, using, or selling RaDaR technology, effective immediately.
NeoGenomics stock tumbled 16.49%, to $17.08 on the volume of 1,408,188 on the Nasdaq. It has traded between $8.71 and $21.22 in the last 52-week period.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.